Pfizer Accupril Patent Victory Could Lead To Influx Of Generics In 2005
Executive Summary
Accupril generics could enter the market as early as 2005 despite a court ruling finding a Pfizer quinapril patent to be valid
You may also be interested in...
Pfizer Obtains Preliminary Injunction Against Teva/Ranbaxy Accupril Generic
A preliminary injunction halting the sale of generic versions of Pfizer's Accupril (quinapril)may be a discouraging sign for generic companies considering "at risk" launches
Pfizer Obtains Preliminary Injunction Against Teva/Ranbaxy Accupril Generic
A preliminary injunction halting the sale of generic versions of Pfizer's Accupril (quinapril)may be a discouraging sign for generic companies considering "at risk" launches
Teva/Ranbaxy launch Accupril generic
Teva/Ranbaxy launch first generic version of Pfizer's Accupril (quinapril) Dec. 15 following FDA approval of Ranbaxy's ANDA. The generic is being manufactured by Ranbaxy, with Teva handling distribution and marketing pursuant to an exclusive supply agreement between the companies. Teva relinquished its 180-day exclusivity, allowing FDA to approve Ranbaxy's ANDA; five other companies hold tentative ANDA approval. Court rulings finding Teva's ANDA infringed a valid Pfizer patent prevented Teva from bringing its own generic to market (1"The Pink Sheet" July 5, 2004, p. 11)...